RevImmune initiated a Phase II trial for the treatment of the t-cell growth factor CYT107.

Many clinical trials of new crown pneumonia focus on reducing the high inflammatory periods that often occur in patients with new coronary pneumonia and can cause substantial damageHowever, there is a growing recognition that high inflammatory periods are usually temporary, often followed by stages of immune failure and T-cell lossThe purpose of the treatment with CYT107 is to significantly increase the number of immune T cells and correct immune failureCYT107 is a therapeutic form of white interleukin-7 (IL-7), the main growth factor of human T cellsMore than 440 patients have been treated with CYT107 in clinical trials, and CYT107 is now known to significantly increase the number and diversity of T cells, including patients in icU with low or failed T-cell levels due to overinfectionCYT107 is excellent lying even in seriously ill patientsThe "ILIAD" Phase II trial for cyT107 treatment of new crown pneumonia in the UK has been selected as a "National Public Health Emergency Focus"The trial began in the UK in mid-May and is currently recruiting patients in 10 locations in the UKTrials in France and Belgium began in early JuneThe United States is also preparing for the experimentIn addition to clinical trials to treat new coronary pneumonia, RevImmune treated 12 patients with new coronary pneumonia on the basis of "sympathetic medication." Data from the "Sympathetic Drug Use" use case supports the ILIAD pilot design and is being published by peer reviewThe role of CYT107/IL-7 recovery of immune levels is fast and long-lastingTreatment is only required twice a week for 2-4 weeksIn clinical trials to date, the efficacy can be seen within a few days of starting administration of CYT107, and has been going on for up to a year after 2-4 weeks of administrationCYT107 maintains the persistence of increased immune cells to prevent late infection, which is a common cause of recurrence and readmissionCYT107/IL-7 can also be easily combined with other treatmentsFor example, CYT107/IL-7 can be combined with Remdesivir, other antiviral therapy and/or anti-inflammatory therapies As a result, CYT107 provides a new way to improve the efficacy of neo-coronary pneumonia and other infectious diseases by safely enhancing the patient's own immune system Rev Immune is working with a team of leading experts in intensive care and immunology, including Lead Researcher Dr Manukar Shankar-Hari, Lead Research Team in the UK, Lead Researcher Dr Bruno Francois, Lead Researcher of the French and Belgian Trial Stakes, and Dr Richard Hotkiss and Ken Remy of Washington University in St Louis, USA Dr Lyle Moldawer and Scott Brakenridge of the University of Florida at Gainesville, and Martin A "Mac" Dr Cheever